ThisCART19A for B-NHL Relapsed After Auto-CAR T

B Cell Lymphoma Clinical Trial

Official title:

A Single-center, Dose Selection Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Auto-CAR T Relapsed B-cell Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05691153
• Other study ID #: SZ5602
• Status: Recruiting
• Phase: Phase 1
• Start date: December 1, 2022
• Est. completion date: November 30, 2025

Study information

• Verified date: December 2022
• Source: The First Affiliated Hospital of Soochow University
• Contact: Jia Chen, M.D., Ph.D.
• Phone: +86-512-67781856
• Email: drchenjia[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and pharmacokinetics of ThisCART19A (allogeneic CAR-T targeting CD19) in patients with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma.

Description:

This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and pharmacokinetics of ThisCART19A in patients with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma. The study will identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile. Before initiating ThisCART19A infusion, subjects will be administered lymphodepletion chemotherapy composed of fludarabine、cyclophosphamide and VP-16. At Day 0 of the Treatment Period, subjects will receive an intravenous (IV) infusion of ThisCART19A. All subjects are monitored during the treatment period through Day 28. All subjects who receive a dose of ThisCART19A will be followed up to 2 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: November 30, 2025
• Est. primary completion date: November 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Voluntarily sign a documented IRB-approved ICF prior to any screening procedure;

2. Gender not restricted, 18 years = age = 75 years;

3. Subjects with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma;

4. Life expectancy = 12 weeks at the time of enrollment;

5. Eastern Cooperative Oncology Group performance status score of 0 or 1;

6. At least one measurable lesion to be assessed, with any nodal lesion > 15mm in LDi (longest diameter) and any extranodal lesion > 10mm in LDi;

7. Subject has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:

1. Adequate marrow function for lymphodepletion chemotherapy: 14 days before enrollment, absolute neutrophil count (ANC) = 1×10^9/L, platelet count = 30×10^9/L, hemoglobin = 80 g/L without blood transfusion;

2. Creatinine clearance = 30 ml/min according to the Cockcroft-Gault formula, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 5 × the upper limit of normal (ULN), total bilirubin = 2×ULN (Subjects with Gilbert syndrome or liver involvement may be enrolled if their total bilirubin is = 3×ULN);

3. Pulmonary function: Baseline oxygen saturation (SaO2) = 92% on room air;

4. Cardiac function:left ventricular ejection fraction (LVEF) = 40% assessed by echocardiography.

8. CD19-positive lymphoma confirmed on a biopsy during screening.

Exclusion Criteria:

1. Allergic to preconditioning measures in the trial.

2. Other malignancies apart from B-cell malignancies within 5 years prior to screening. (Subjects with cured skin squamous carcinoma, basal carcinoma, non-primary invasive bladder cancer, localized low-risk prostate cancer, in situ cervical/breast cancer can be recruited.)

3. Severe active infection (Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted).

4. Pulmonary embolism (PE) within 3 months prior to enrollment.

5. Intolerant severe cardiovascular and cerebrovascular diseases and hereditary diseases assessed by the investigator prior to enrollment.

6. Gastrointestinal involvement at risk of active bleeding.

7. Massive pericardial effusion, symptomatic thoracic or abdominal effusion.

8. Presence of CNS involvement (both primary and secondary) at screening confirmed by imaging or CSF testing.

9. Active hepatitis B virus (serum HBV-DNA = 2000 IU/mL), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or active syphilis infection prior to enrollment. (Patients with HBV-DNA < 2000 IU/mL can be enrolled, but should be administered antiviral drugs such as entecavir and tenofovir with relative clinical indicators monitored simultaneously during the treatment.)

10. Less than 100 days after allogeneic hematopoietic stem cell transplantation.

11. Vaccinated with influenza vaccine within 2 weeks prior to lymphodepletion chemotherapy. (Patients vaccinated with SARS-COV19 vaccine or inactivated; live/non-live adjuvant vaccines can be enrolled.)

12. Under treatment for graft versus host disease (GvHD). (GvHD cured subjects who had stopped immunosuppressive drugs for at least 1 month can be enrolled.)

13. Female subjects who are pregnant, breastfeeding or planning for pregnancy within 1 year after CAR-T cell infusion, or male subjects whose partners are planning for pregnancy within 1 year after CAR-T cell infusion;

14. Any conditions that would, in the investigator's assessment, increase risks in patients or interfere with the outcomes of the trial.

Related Conditions & MeSH terms

• B Cell Lymphoma
• CAR
• Lymphoma
• Lymphoma, Non-Hodgkin
• Relapsed Non-Hodgkin Lymphoma

Intervention

Drug:
• ThisCART19A with Dose Level 1
ThisCART19A,2×10^6 cells/kg(Single dose of Allogeneic Anti-CD19 CAR T cells will be infused), after the lymphodepletion conditioning of fludarabine, CTX and VP-16
• ThisCART19A with Dose Level 2
ThisCART19A,3×10^6 cells/kg(Single dose of Allogeneic Anti-CD19 CAR T cells will be infused), after the lymphodepletion conditioning of fludarabine, CTX and VP-16

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Soochow University	Suzhou	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Soochow University	Fundamenta Therapeutics, Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BOR	Best Overall Response Rate	3 month
Secondary	ORR	Objective response rate	2 year
Secondary	CR	Complete response rate	2 year
Secondary	TTR	Time to response	3 month
Secondary	DOR	Duration of response	2 year
Secondary	EFS	Event-free survival	2 year
Secondary	PFS	Progression-free survival	2 year
Secondary	OS	Overall survival	2 year